AHF Challenges Gilead over AIDS Drug Price Gouging of U.S. Gov’t Programs on ‘Stribild’

  AHF Challenges Gilead over AIDS Drug Price Gouging of U.S. Gov’t Programs on
  ‘Stribild’

  Gilead charges $28.5K—nearly $12,000 more in the United States for its new
four-in-one HIV drug, Stribild, than other countries, such as Canada—where the
 drug is priced at only $16,600 per patient per year. AHF reiterates call for
       Gilead to immediately lower the price of Stribild for all payers

Business Wire

LOS ANGELES -- January 29, 2013

As part of its ongoing campaign to pressure Gilead Sciences, Inc. and educate
the public about the exorbitant price of HIV/AIDS medications, AIDS Healthcare
Foundation (AHF) today challenged the company over its price discrimination
for its four-in-one HIV drug, Stribild. In the United States, Gilead charges a
yearly wholesale price (WAC) of $28,500 per patient for Stribild while
charging only $16,600 in Canada – a difference of nearly $12,000 per patient.
(At present, the US dollar is worth .99 of Canadian dollar).

“There is no justification for Gilead to continue to charge $28,500 for
Stribild in the U.S. while it is willing to cut the price in Canada and other
countries,” said AHF President Michael Weinstein. “Gilead has made it loud and
clear that without the kind of price controls that exist in Canada and Europe,
its greed and blatant disregard for the health of its customers—people with
HIV/AIDS—will continue undiminished.”

Stribild, Gilead’s four-in-one AIDS treatment combination, was approved by the
Food and Drug Administration (FDA) in early September and immediately priced
by Gilead at $28,500 per patient, per year, Wholesale Acquisition Cost (WAC).
That price was over 35% more than Atripla, the company’s best selling
combination HIV/AIDS treatment, and made Stribild the highest priced first
line combination AIDS therapy today.

Already this year, on January 1^st, Gilead raised the prices of four key AIDS
medications in the U.S. by an average of 6%, including the price of Atripla,
its best-selling three-in-one combination treatment, the price of which was
increased by 6.9% to a Whole Acquisition Cost (WAC) of $1,878.23 per patient,
per month. The other three HIV/AIDS medications that saw price hikes are
Complera, which was raised by 5.8% to a WAC of $1,936.53; Emtriva, by 5.5% to
a WAC of $478.45; and Viread, by 6% to a WAC of $771.39.

In late November, CATIE-News, an online site which states it is “Canada’s
source for HIV and Hepatitis C information,” reported the Canadian price for
Stribild is $16,600 per patient per year. This is a 42% cost reduction
compared to the $28,500 Stribild costs per patient per year in the US. This
price reduction highlights Gilead's apparent willingness to gouge the pockets
of US taxpayers and government-funded programs like the AIDS Drug Assistance
Program (ADAP) while making price concessions to countries with sometimes
stronger economies than the US.

About AIDS Healthcare Foundation

AIDS Healthcare Foundation (AHF), the largest global AIDS organization,
currently provides medical care and/or services to nearly 200,000 individuals
in 28 countries worldwide in the US, Africa, Latin America/Caribbean, the
Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit
our website: www.aidshealth.org, find us on Facebook:
www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare.

Contact:

AIDS Healthcare Foundation
Tim Boyd
(213) 590-7375 mobile
tim.boyd@aidshealth.org
or
Ged Kenslea
Telephone: (323) 308-1833
Mobile: (323) 791-5526
gedk@aidshealth.org
 
Press spacebar to pause and continue. Press esc to stop.